PubMed Health⌕ Search

Biomedical subjects

G Bessard

Publications and source records attributed to G Bessard.

At least 55 records · Page 3Linked to original sources
PubMed1998

Functional assessment of human femoral arteries after cryopreservation.

PURPOSE: An established method of cryostorage that might preserve the vascular and endothelial responses of human femoral arteries (HFAs) to be transplanted as allografts was studied. METHODS: HFAs were harvested from multiorgan donors and stored at 4 degrees C in Belzer solution before cryostorage. One hundred eleven HFA rings were isolated and randomly assigned to 1 control group of unfrozen HFAs and 2 groups of HFAs cryopreserved for 7 and 30 days, respectively. Cryopreservation was performed in Elohes solution containing dimethyl sulfoxide (1.8 mmol/L), and the rate of cooling was 1.6 degrees C/min, until -141 degrees C was reached. The contractile and relaxant responses of unfrozen and frozen/thawed arteries were assessed in organ bath by measurement of isometric force generated by the HFAs. RESULTS: After thawing, the maximal contractile responses to all the contracting agonists tested (KCl, U46619 [a thromboxane A2-mimetic], norepinephrine, serotonin, and endothelin-1) were in the range of 7% to 34% of the responses in unfrozen HFAs. The endothelium-independent relaxant responses to forskolin and verapamil were weakly altered, whereas the endothelium-independent relaxant responses to sodium nitroprusside were markedly reduced. Cryostorage of HFAs also resulted in a loss of the endothelium-dependent relaxant response to acetylcholine. The vascular and endothelial responses were similarly altered in the HFAs cryopreserved for 7 and 30 days. CONCLUSION: The cryopreservation method used provided a limited preservation of HFAs contractility, a good preservation of the endothelium-independent relaxant responses, but no apparent preservation of the endothelium-dependent relaxation. It is possible that further refinements of the cryopreservation protocol, such as a slower rate of cooling and a more controlled stepwise addition of dimethyl sulfoxide, might allow better post-thaw functional recovery of HFAs.

Cryopreservation↗
PubMed1998

Frusemide inhibits angiotensin II-induced contraction on human vascular smooth muscle.

AIMS: Frusemide is widely used in the treatment of acute pulmonary oedema, chronic congestive heart failure and, to a lesser degree, in the treatment of hypertension. Evidence suggests that frusenuide exerts an anti-vasoconstrictor effect independent of its diuretic properties. Since angiotensin II is a highly potent vasoconstrictor involved in the pathophysiology of these diseases, we have investigated the effect of frusemide on the contraction elicited by angiotensin II on human internal mammary artery (IMA) and saphenous vein (SV). METHODS: Rings of IMA and SV were suspended for isometric tension recording in organ baths. Concentration-response curves to angiotensin II were performed in the absence (control) or in the presence of frusemide (10(-6) to 10(-3) M). In addition, the effect of frusemide was evaluated after cyclooxygenase inhibition by indomethacin (10(-6) M) and was compared with those of the other loop diuretic bumetanide (10(-4) M). RESULTS: Frusemide induced a concentration-dependent decrease of the contraction elicited by angiotensin II on IMA and SV. On both vessels, the inhibitory effect on the maximal contraction to angiotensin II was significant with concentrations of frusemide from 10(-5) to 10(-3) M. Angiotensin II potency (pD2) was only reduced by 10(-3) M frusemide. The effect of frusemide was not altered in the presence of indomethacin. Bumetanide was less potent than frusemide in inhibiting angiotensin II-induced contractions in both IMA and SV. CONCLUSIONS: Frusemide, at concentrations in the therapeutic range (10(-5) M), inhibits angiotensin II-induced contraction on human isolated IMA and SV. This inhibitory effect is cyclooxygenase independent and appears mediated, at least in part, by inhibition of Na+/K+/2Cl- symport. Reduction in the vasoconstrictor effect of angiotensin 1 may be involved in the therapeutic efficacy of frusemide.

Angiotensin II↗
PubMed1997

Direct analysis of fluoxetine and norfluoxetine in plasma by gas chromatography with nitrogen-phosphorus detection.

A quantitative method for the simultaneous GC resolution and detection of fluoxetine and his metabolite norfluoxetine in human plasma was developed. The procedure required 1.0 ml of plasma, extraction with a mixed organic solvent and injection into a capillary gas chromatograph with an OV-1 fused-silica column coupled to a nitrogen-phosphorus detector. The calibration curves were linear over the range 5-3000 ng/ml. The detection limits were 0.3 and 2 ng/ml for fluoxetine and norfluoxetine, respectively. The assay is suitable for routine analysis.

Chromatography, Gas↗
PubMed1997

Modified method of nalbuphine determination in plasma: validation and application to pharmacokinetics of the rectal route.

A solid-phase extraction (SPE) procedure was developed for the quantification of nalbuphine in a small volume (500 microliters) of human plasma with subsequent assay by high-performance liquid chromatography (HPLC) and electrochemical detection using 6-monoacetylmorphine as internal standard. Plasma was extracted using Bond Elute certified extraction columns (LCR: 10 ml, 130 mg) after conditioning with methanol and 0.2 M Tris buffer (pH 8). Elution was performed with a CH2Cl2-isopropanol-NH4OH (79:20:1, v/v). The organic phase was evaporated to dryness and resuspended in HPLC mobile phase containing 2% isopropanol. Linearity was assessed over the 5-100 ng/ml concentration range and a straight line passing through the origin was obtained. Experiments with spiked plasma samples resulted in recoveries of 95 +/- 5.4% and 98 +/- 6.2% for nalbuphine and 6-monoacetylmorphine, respectively. The optimal pH conditions for the SPE were found at pH 8. The intra-day coefficients of variation (C.V.) for 5, 40, and 100 ng/ml were 5.3, 3.0 and 2.3% (n = 8) and the inter-day C.V.s were 7.7, 3.2 and 3.5% (n = 10), respectively. The detection limit for 500 microliters plasma sample was 0.02 ng/ml and the limit of quantification 0.1 ng/ml (C.V. = 12.4%). The ease of the proposed method of analysis, as well as its high accuracy and sensitivity allow its application to pharmacokinetic studies. A preliminary kinetic profile of nalbuphine after rectal administration in a pediatric patient is presented.

Administration, Rectal↗
PubMed1997

Thromboxane A2 and related prostaglandins in airways.

Asthma is now thought to be a chronic inflammatory disease of the airways. The roles of prostanoids, thromboxane A2 (TXA2) and the prostaglandins (PGs) in the pathogenesis and pathophysiology of asthma have fostered a wealth of studies but remain controversial. TXA2 and the bronchoconstrictor PGs, PGD2 and PGF2 alpha, are generated in greater amounts in asthmatic than in normal subjects. TXA2 is a potent constrictor of airway smooth muscle, an inducer of acetylcholine release and of airway microvascular leakage. It may participate in the thickening and the remodeling of the airway wall which may contribute to the airway hyperresponsiveness, a typical feature of asthma. Strategies for inhibition of TXA2 effects include antagonism of the TXA2 receptor (TP receptor) and inhibition of the thromboxane synthase. TP receptor antagonists could block the effects of all the bronchoconstrictor prostanoids because TXA2 as well as the bronchoconstrictor PGs act through activation of lung TP receptor. The recent development of specific and potent TP receptor antagonists and inhibitors of thromboxane synthase has provided tools to assess the role of TXA2 and broncho-constrictor PGs in the pathophysiology of asthma.

15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5↗
PubMed1997

Pharmacokinetics of intrarectal nalbuphine in children undergoing general anaesthesia.

The pharmacokinetics of nalbuphine (0.3 mg/kg) administered by the rectal route were studied in ten children undergoing general anaesthesia for minor surgery. Blood sampling was carried out for 8 h after rectal administration and plasma drug concentrations were measured by high performance liquid chromatography using electrochemical detection after an optimized solid-phase extraction procedure. The mean time to achieve the maximum plasma concentration (Cmax = 24 +/- 15 ng/mL) was 25 +/- 11 min and the elimination half-life was 2.7 +/- 0.7 h. The coefficients of variation for Cmax and the concentration-time curve (AUC) were 62 and 68%, respectively. Although rectal absorption is considered irregular, the large intersubject variability is also explainable by a variable hepatic bypass for a drug, like nalbuphine, that undergoes extensive first-pass metabolism. No problem of analgesic efficacy or of local tolerance was reported. In conclusion, the rectal route of administration provides a rapid and reliable absorption of nalbuphine.

Administration, Rectal↗
PubMed1997

Characterization of the production of acetaldehyde by astrocytes in culture after ethanol exposure.

The nervous system is one of the main targets of ethanol toxicity. Astrocytes might play an important role in ethanol-induced brain toxicity, because their integrity is essential for the normal growth and functioning of neurons. On the other hand, acetaldehyde has been implicated as a mediator in some of the biochemical, pharmacological, and behavioral effects of ethanol. The present study aimed at demonstrating the ability of astrocytes in culture to produce acetaldehyde from ethanol. Significant metabolization of ethanol with production of acetaldehyde was demonstrated in the primary culture of astrocytes. This production was quite low, compared with that usually observed in hepatocytes, but was in the same range as that measured in whole brain homogenates and corresponded to biologically active levels. Such a demonstration could bring new elements for understanding of ethanol neurotoxicity.

Acetaldehyde↗
PubMed1997

[Leukotriene antagonists: a new approach in the treatment of asthma].

Inflammation plays an essential role in the genesis of airflow obstruction and bronchial hyper-reactivity in the early stages of clinical asthma. The treatment of bronchial inflammation has become an essential element in the therapeutic strategy and principally rests on inhaled glucocorticoids. Amongst a number of inflammatory mediators leukotrienes occupy a privileged place by the power of their inflammatory and constrictor effects on bronchial smooth muscles. These properties have justified the clinical development of inhibitors of their synthesis and of specific antagonists to their receptors. Leukotriene antagonists are specific for a sub type of leukotriene receptors C4, D4 and E4 which is implicated in the majority of the bronchial constrictor and inflammatory effects of leukotrienes. The antagonists of Cys-LT1 receptor but also the inhibitors of the leukotriene synthesis exert an additive bronchodilator effect to those of B2 stimulants confirming an efficacious protection vis a vis bronchial provocation tests and above all they improve the clinical scores, lung function and also enable a decrease in the consumption of beta 2 agonists. The marketing of these products represents a major event because it corresponds to the advent of a new therapeutic class. The ease of administration by the oral route, their demonstrated efficacy and their good tolerance profile (in particular for ICI 204.219, and antagonists to Cys-LT1 receptors) are elements which foresee a success for this new asthmatic treatment. However numerous studies, notably comparative studies vis a vis reference treatments will be necessary to define their place in the strategic approach to the treatment of asthma.

Anti-Asthmatic Agents↗
PubMed1996

Simultaneous determination of zolpidem and zopiclone in human plasma by gas chromatography-nitrogen-phosphorus detection.

A simple, specific and selective method for the simultaneous determination of zolpidem and zopiclone in human plasma is described. After a liquid-liquid extraction, the extract is injected into a capillary gas chromatograph with an OV-1 fused-silica column coupled to a nitrogen-phosphorus detector. The detection limits are 1 and 2 ng/ml for zolpidem and zopiclone, respectively. The method described is reproducible and linear over a range of concentrations, rendering it suitable for use for pharmacokinetic studies or toxicological evaluations. Absolute identification of the chromatographed compounds is accomplished by gas chromatography--mass spectrometry in both electron-impact and positive-ion chemical ionisation modes.

Artifacts↗
PubMed1996

Therapeutic monitoring of nalbuphine: transplacental transfer and estimated pharmacokinetics in the neonate.

Nalbuphine, a mixed agonist-antagonist opiate, is commonly used as a systemic analgesic during labour. Recent reports of perinatal adverse effects prompted us to carry out therapeutic nalbuphine monitoring in obstetric analgesia. Because data on fetomaternal transfer are scarce and the pharmacokinetics of this drug in the neonate are largely unknown, we report data obtained from 28 parturients treated with nalbuphine either intramuscularly and/or intravenously during labour. Plasma nalbuphine levels were measured by high-performance liquid chromatography (HPLC) with electrochemical detection. At delivery, 30-150 min after maternal administration, nalbuphine concentrations ranged from 5.0 to 79.2 ng.ml-1 in mother plasma samples and from 3.0 to 46.6 ng.ml-1 in umbilical cord plasma samples. Nalbuphine concentrations were highly correlated to dose. The fetomaternal ratio was high: 0.74 and not correlated to the administered dose of nalbuphine. An estimated plasma half-life of 4.1 h was calculated from two determinations in the neonate based on the assumption of a monoexponential decay of nalbuphine concentrations. Apart from a flattening of the fetal heart rate tracing in 54% of the cases, only one neonate had a low Apgar score at birth. The apparent prolonged half-life of nalbuphine in the neonate indicates the usefulness of an intramuscular injection of naloxone to prevent recurrence of cardiorespiratory depression due to nalbuphine administration to the mother.

Adult↗
PubMed1995

[Hematotoxicity caused by azathioprine genetically determined and aggravated by xanthine oxidase deficiency in a patient following renal transplantation].

Azathioprine is an immunosuppressor used with ciclosporin and corticosteroids after organ transplantation. Azathioprine is rapidly transformed into 6-mercaptopurine which in turn is metabolized by three competitive pathways: a) intracellular hypoxanthine guanine phosphoribosyl transferase leads to 6-thioguanine nucleotides which can damage chromosome DNA; b) thiopurine methyltransferase produces inactive methylated derivatives; c) xanthine oxidase produces thiouric acid. Due to inter-individual variations in the later two pathways, azathioprine dose must be adapted to each patient. A 48-year-old female patient underwent renal transplantation in 1994 and was given immunosuppressive therapy combining thymoglobulins, azathioprine and ciclosporin. Severe leukopenia (< 3000/mm3) occurred on day 5 requiring withdrawal of azathioprine. Known hypouricaemia (< 50 mumol/l) suggested xanthine oxidase deficiency. Laboratory results confirmed xanthine oxidase deficiency and also revealed reduced thiopurine methyltransferase activity (14.9 pmol/h/mg Hb). Azathioprine toxicity was confirmed by regression of the leukopenia after withdrawal and recurrence at rechallenge. Xanthine oxidase deficiency occurs in 2% of the general population. Reduced thiopurine methyltransferase activity affects 11% of the population. The combined presence of these two genetic anomalies led to early and sudden intolerance to azathioprine and emphasize the need to develop new immunosuppressor agents degraded by other metabolic pathways.

Azathioprine↗
PubMed1995

Rapid and sensitive high-performance liquid chromatographic assay for nalbuphine in plasma.

A simple and reliable reversed-phase high-performance liquid chromatographic method with adequate internal analog standardization and coulometric detection is described for the quantification of nalbuphine in plasma samples. The lower limit of detection was estimated to be 0.1 ng/ml. For routine analysis, the limit of quantification was set at 0.5 ng/ml and only a small plasma volume (500 microliters) was required. The nalbuphine calibration curve was linear over the concentration range 0-100 ng/ml. The recoveries of nalbuphine and 6-monoacetylmorphine, used as internal standard, were close to 85%. Due to the small sample volume of blood required, this highly sensitive, accurate and specific method is suitable for pharmacokinetic studies of nalbuphine, and particularly for drug monitoring in neonates born from mothers treated with nalbuphine.

Chromatography, High Pressure Liquid↗
PubMed1993

Simultaneous determination of trimipramine and desmethyl- and hydroxytrimipramine in plasma and red blood cells by capillary gas chromatography with nitrogen-selective detection.

A simple procedure is described that permits the simultaneous determination of trimipramine and its two major metabolites, desmethyl- and hydroxytrimipramine, in human plasma or red blood cells (RBCs) at therapeutic concentrations. The extracted biological fluids are injected into a capillary gas chromatograph with an OV-1 fused-silica column coupled to a nitrogen-phosphorus-selective detector. The limit of determination for trimipramine is 3 ng/ml and for that desmethyl- and hydroxytrimipramine is 4 ng/ml. The method permits the RBC/plasma ratios to be determined and to be correlated with the clinical response.

Chromatography, Gas↗
PubMed1983

Effect of sodium benzoate on the cutaneous bilirubin content of the adult Gunn rat.

Na benzoate, which dissociates intravascular bilirubin-albumin complexes, might thus have the potential for driving bilirubin from the plasma into tissues such as the skin. We investigated this hypothesis in the adult Gunn rat. As others, we observed an early fall in blood bilirubin concentration after intraperitoneal Na benzoate injection, without any change in skin bilirubin content. Nevertheless, we observed a significant decrease (p less than 0.01) in skin bilirubin content at 24 and then 48 h after Na benzoate injection, at which times blood bilirubin remained at a low level. The phenomenon was reversible since, at 8 days after Na benzoate injection, blood and skin bilirubin contents had returned to control values. Regarding the decrease in skin bilirubin content after Na benzoate injection we described a dose-effect relationship. So, we could not confirm our hypothesis. We concluded that the phenomenon we observed is probably due to a shift in the distribution equilibrium of the pigment between serum, skin and other tissues.

Animals↗
PubMed1982

A spectrophotometric assay of skin bilirubin in adult Gunn rats.

The present study was undertaken to assess the value of a spectrophotometric method for the assay of bilirubin content in Gunn rat skin. The pigment extraction was performed by incubating skin strips in a barbital-acetate buffered methanol-chloroform mixture at pH 7 for 90 min. The procedure yielded an overall recovery average of 93 +/- 9% which was not influenced when the incubation time was varied from 1 to 2.5 h. The bilirubin concentration in skin extracts was calculated from spectrophotometric absorbance readings and according to the molar extinction coefficient of the pigment in chloroform. Bilirubin appeared to remain stable during the analytical process. The mean bilirubin content as measured by this method was 1.88 mumol/100 g (1.1 mg/100 g). It is concluded that the proposed method is well suited for the investigation of bilirubin skin metabolism.

Animals↗